← Open Payments lookup

OLABIMPE LABIYI: Open Payments

NPI 1548973852 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$2,179 in 94 payments from 12 companies in 2025. Trend: 2023 $738 · 2024 $1,133 · 2025 $2,179

Food & beverage: $2,179
CompanyPaymentsAmount
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)18$419
Otsuka America Pharmaceutical, Inc.15$370
E.R. Squibb & Sons, L.L.C.9$268
ABBVIE INC.13$235
Teva Pharmaceuticals USA, Inc.12$214
Axsome Therapeutics, Inc.7$178
Vanda Pharmaceuticals Inc.9$149
Supernus Pharmaceuticals, Inc.3$141
Neurocrine BioSciences, Inc.4$114
Janssen Pharmaceuticals, Inc2$61

Products named: CAPLYTA, REXULTI, COBENFY, VRAYLAR, Auvelity, AUSTEDO XR, FANAPT, Qelbree.

Industry payments across TX — which companies pay providers there.